SET and neurodegenerative disease: SET is mainly located within the nucleus of the cells (Figure 1A); however, in many forms of cancers and neurodegenerative diseases, SET translocates from its primarly nuclear localization to the cytoplasm, where it can form an inhibitory interaction with PP2A.